CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	2.98M 2.61M 2.41M 2.22M 4.22M 284M 4.29M 28.75M 11.29M 140M 11.2M 10.96M 482M	P/E 2026 *	-0.1x	P/E 2027 *	-0.1x
Enterprise Value	2.98M 2.61M 2.41M 2.22M 4.22M 284M 4.29M 28.75M 11.29M 140M 11.2M 10.96M 482M	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	53.62%	Yield 2026 *	-	Yield 2027 *	-

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-14	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-20	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
04-20	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03-03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03-03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	20/07/2025
Kun Qian DFI	Director of Finance/CFO	44	15/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	31/12/2016

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	31/03/2013
Zhen Bo Su BRD	Director/Board Member	50	20/03/2023
Thomas Folinsbee BRD	Director/Board Member	59	20/03/2023

ENTREMED Share Price Nasdaq

Stocks

Pharmaceuticals

Valuation: ENTREMED

Latest news : ENTREMED

Press Releases: ENTREMED

Managers and Directors: ENTREMED

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-2.33%	-2.09%	+50.33%	+162.29%	1,060B
JOHNSON & JOHNSON	-0.82%	-2.30%	+62.97%	+61.11%	619B
ABBVIE INC.	-0.73%	-4.98%	+27.22%	+84.46%	438B
ROCHE HOLDING AG	+0.33%	-1.17%	+27.98%	+26.90%	333B
NOVARTIS AG	-0.02%	-2.85%	+25.27%	+44.88%	282B
ASTRAZENECA PLC	-3.89%	-11.22%	+20.78%	+26.07%	267B
NOVO NORDISK A/S	+0.66%	-1.42%	-29.26%	-39.30%	218B
AMGEN INC.	-0.06%	-2.88%	+20.98%	+61.70%	196B
GILEAD SCIENCES, INC.	-3.72%	-1.10%	+13.35%	+71.53%	161B
Average	-0.89%	-3.25%	+24.40%	+55.51%	397.1B
Weighted average by Cap.	-0.56%	-2.96%	+35.28%	+81.27%

	2026 *	2027 *
Net sales	-	-
Net income	-24.73M -21.63M -19.95M -18.42M -34.96M -2.36B -35.55M -238M -93.6M -1.16B -92.84M -90.82M -3.99B	-26.51M -23.19M -21.39M -19.75M -37.48M -2.53B -38.11M -256M -100M -1.25B -99.54M -97.37M -4.28B
Net Debt	-	-

End-of-day quote Nasdaq Other stock markets
- ^USD	-